Aug
25 2010

New Jersey Uses Former Landfill Site for Algae Project

A multimillion-dollar ethanol plant is planned for a former landfill site, but members of the community can get a sneak peak of the technology in action next week. Garden State Ethanol will demonstrate extracting the fuel from algae at a prototype site located on Washington Avenue at the old Gentilini Ford building.

The USDA is scheduled to visit Woodbine next Thursday to present a check for $98,000 to begin to transform the landfill into a production facility that could employ as many as 50 people.

The facility is still more than a year away, which is why the prototype is being used to demonstrate the technology next week. “It’s going to take about a year to get permits for the site approved, and we’ll just move from there,” Mayor William Pikolycky said. When the final facility reaches full production, it’s expected that 25 million gallons of ethanol and 10 million gallons of biodiesel will be produced at the site annually.

Aug
17 2010

Daily supplements of astaxanthin may improve HDL ‘good’ cholesterol levels, suggests new data from a human trial

Doses up to 18 milligrams per day for 12 weeks improved blood levels of HDL cholesterol, as well as adiponectin concentrations, a protein hormone linked to various metabolic processes, according to findings published in Atherosclerosis.

Researchers from Jikei University Kashiwa Hospital in Japan and Fuji Chemical Industry used Fuji’s commercially available AstaReal astaxanthin ingredient, and the trial involved 61 non-obese people with mildly elevated triglyceride levels.

According to the researchers, the potential benefits of astaxanthin with regards to HDL cholesterol and triglycerides have been demonstrated previously in animal studies, but supporting data from humans have been lacking.

More info

Aug
17 2010

International Seafood & Health Conference & Exhibition – Australia, November 6 – 10, 2010

It is important to understand that this is not a fisheries conference, it is a health conference, but one where the participants all share a common interest and will communicate information about the very latest medical research into all health aspects of the benefits of seafood. New discoveries and a deeper understanding of the health benefits of seafood are occurring at a rapid rate and this conference will highlight the very latest information available.

It is anticipated to attract up to 1,000 participants made up of the world’s leading health researchers, environmental researchers, medical practitioners, nutrition educators and policy-makers, probably some 50 or more countries will be represented, from the Americas and Europe to Asia and the South Pacific.

The conference will be supported by a Trade display of industry, scientific and health/environment exhibitors to ensure the attendees leave with the very latest knowledge in all these important areas. The conference program will embrace the public health and wellbeing by seeking presenters to deliver the latest development of these types of subjects: Obesity, Child Nutrition, Brain Nutrition, Health Benefits of Fish Consumption, Nutrition and Public Health, The role of fish and seafood in human cognitive development, Diabetes, Heart Health, education issues in nutrition and public health, and importantly Sustainability of Fisheries Resources and the future of aquaculture.

More info

Aug
16 2010

Portland, Maine’s Ocean Approved Seaweed Products begins further expansion

Like so many entrepreneurial ventures with food products, Ocean Approved frozen seaweed started with a pot simmering on a kitchen stove. Now, with a $95,000 NOAA Small Business Innovation Research Program Phase I Grant and an experimental lease to raise seaweed near Little Chebeague Island, the first lease of its kind in the U.S., the company, which has grown steadily since its inception, is poised to move towards large-scale commercial production of seaweed.

In the first year of business, Tolleff Olson, the company’s founder, did all the work, gathering, processing and marketing. Two years ago, he was joined by business partner Paul Dobbins, who runs the office. According to Dobbins, Olsen is “the visionary” and does everything else. They now have 10 part-time employees.

During the past year, sales have more than doubled. At first, Olsen sold the seaweed products to four Portland stores; that has increased to 17 Whole Foods Markets and 72 specialty and natural foods stores, including two venues in Los Angeles. In June, as a result of contacts made while serving their seaweed at the NOAA Fish Fry for NOAA employees and guests in Washington, D.C., Ocean Approved gained orders from a chain of natural food stores in the D.C. area.

More info

Aug
16 2010

Seaweed-derived products from NZ Biotech company building sales in overseas markets

Nemidon, a NZ company that makes a range of gels derived from seaweed, including moisturiser, treatments for sports injuries, muscle aches and joint pain, is growing its overseas markets.

Ninety per cent of its products are exported and those overseas sales got a boost more than 10 years ago when founder Margaret Holloway took Nemidon’s gel on a marketing trip to a United States triathlon trade show. Offering it to a visitor proved to be a good move – he turned out to be a member of the US Olympic committee.

“The visitor who came to our booth used the gel and was impressed by its qualities. He then asked if we would be prepared to put the gel up for the US market,” Hollway said.

“What that has done for us is given us the credibility we needed early on to tackle our global push, as well as the credibility to enter the Aussie market.”

Nemidon’s gels are formulated using a seaweed extract that acts as a carrier delivering the active ingredients needed for rehabilitation of the skin.

More info

Aug
16 2010

Cyanotech reports steady Q1 2011 for both its spirulina and astaxanthin products

The Hawaiian healthy algae specialist has reported revenues of $3,856,000 for the quarter ended 30 June, compared to $4,021,000 for the same period last year. Gross profit margin remained at 43 per cent, and gross profit was $1657,000, down slightly from $1733,000.

Its sales have been fairly evenly split between its two main products, spirulina (accounting for 51 percent of revenues) and astaxanthin (49 percent).

The company has been shifting its emphasis onto its consumer products, sold under its Nutrex Hawaii brand, and is aiming to introduce them to a broader consumer base than previously.

More info

Aug
07 2010

New Network of Northern Germany Marine Biotechnology Firms and Researchers

On June 15, 2010, at the Leibniz Institute of Marine Sciences (IFM-GEOMAR), 20 research teams and companies in the marine biotechnology sector have signed an agreement on the creation of the North German Network of marine biotechnology –  focused on active substances and materials from marine sources, including microorganisms.

The material from the sea may have applications as varied as drugs from marine bacteria, algae-based cosmetics or pesticides from environmental marine sponges. Johannes Imhoff, Director of the Center for Active Substances in the IFM-GEOMAR ( KiWiZ ), is the initiator of this agreement. “We want to create a professional network and innovative research that stimulates the strength of competitiveness and innovation of marine biotechnology in northern Germany”, he explains.

The 20 partners of the network come from Mecklenburg -Western Pomerania, Schleswig -Holstein and Hamburg. The network’s activities focus on products derived from marine organisms that may have applications in medicine and healthcare technologies, plant protection, health, industrial biotechnology, cosmetic and food industries.

More info

Aug
06 2010

Sponge Genome Reveals Animal, Cancer Origins

In a paper appearing in the recent issue of the journal Nature, a team of researchers led by Daniel Rokhsar of the Univ. of California, Berkeley, and the Department of Energy’s Joint Genome Institute (JGI), report the draft genome sequence of the sea sponge Amphimedon queenslandica and several insights the genome gives into the origins of both the first animals and cancer.

“Our hypothesis is that multicellularity and cancer are two sides of the same coin,” says Rokhsar, professor at UC Berkeley. “If you are a cell in a multicellular organism, you have to cooperate with other cells in your body, making sure that you divide when you are supposed to as part of the team. The genes that regulate this cooperation are also the ones whose disruption can cause cells to behave selfishly and grow in uncontrolled ways to the detriment of the organism.”

As part of the new analysis, the team looked in the sponge genome for more than 100 genes that have been implicated in human cancers and found about 90 percent of them. Future research will show what roles these genes play in endowing sponge cells with team spirit.

More info

Aug
04 2010

MDPI Office of the Publisher announces publication of new Marine Drugs issue

MDPI announces publication of the following issue: Mar.
Drugs, Volume 8, Issue 7 (July 2010), Pages 1962-2222 at
http://www.mdpi.com/1660-3397/8/7/

Table of Contents:

Jiali Zhang, Wenshui Xia, Ping Liu, Qinyuan Cheng, Talba Tahi, Wenxiu Gu
and Bo Li
Review: Chitosan Modification and Pharmaceutical/Biomedical Applications
Mar. Drugs 2010, 8(7), 1962-1987; doi:10.3390/md8071962
http://www.mdpi.com/1660-3397/8/7/1962

Feisal Khoushab and Montarop Yamabhai
Review: Chitin Research Revisited
Mar. Drugs 2010, 8(7), 1988-2012; doi:10.3390/md8071988
http://www.mdpi.com/1660-3397/8/7/1988

Sandra Anne Banack and Paul Alan Cox
Correction: Correction: Banack, S.A. et al. Production of the Neurotoxin
BMAA by a Marine Cyanobacterium. Mar. Drugs 2007, 5, 180–196
Mar. Drugs 2010, 8(7), 2013; doi:10.3390/md8072013
http://www.mdpi.com/1660-3397/8/7/2013

Chih-Yang Liu, Tsong-Long Hwang, Mei-Ru Lin, Yung-Husan Chen, Yu-Chia
Chang, Lee-Shing Fang, Wei-Hsien Wang, Yang-Chang Wu and Ping-Jyun Sung
Article: Carijoside A, a Bioactive Sterol Glycoside from an Octocoral
Carijoa sp. (Clavulariidae)
Mar. Drugs 2010, 8(7), 2014-2020; doi:10.3390/md8072014
http://www.mdpi.com/1660-3397/8/7/2014

Vítor Ramos and Vítor Vasconcelos
Review: Palytoxin and Analogs: Biological and Ecological Effects
Mar. Drugs 2010, 8(7), 2021-2037; doi:10.3390/md8072021
http://www.mdpi.com/1660-3397/8/7/2021

Laurie O’Sullivan, Brian Murphy, Peter McLoughlin, Patrick Duggan,
Peadar G. Lawlor, Helen Hughes and Gillian E. Gardiner
Review: Prebiotics from Marine Macroalgae for Human and Animal Health
Applications
Mar. Drugs 2010, 8(7), 2038-2064; doi:10.3390/md8072038
http://www.mdpi.com/1660-3397/8/7/2038

Guoliang Wang, Ge Zhao, Yanbin Feng, Jinsong Xuan, Jianwei Sun, Baotai
Guo, Guoyong Jiang, Manli Weng, Jianting Yao, Bin Wang, Delin Duan and Tao
Liu
Article: Cloning and Comparative Studies of Seaweed Trehalose-6-Phosphate
Synthase Genes
Mar. Drugs 2010, 8(7), 2065-2079; doi:10.3390/md8072065
http://www.mdpi.com/1660-3397/8/7/2065

Graziano Guella, Danielle Skropeta, Graziano Di Giuseppe and Fernando Dini
Review: Structures, Biological Activities and Phylogenetic Relationships
of Terpenoids from Marine Ciliates of the Genus Euplotes
Mar. Drugs 2010, 8(7), 2080-2116; doi:10.3390/md8072080
http://www.mdpi.com/1660-3397/8/7/2080

Ratih Pangestuti and Se-Kwon Kim
Review: Neuroprotective Properties of Chitosan and Its Derivatives
Mar. Drugs 2010, 8(7), 2117-2128; doi:10.3390/md8072117
http://www.mdpi.com/1660-3397/8/7/2117

Scharri J. Ezell, Haibo Li, Hongxia Xu, Xiangrong Zhang, Evrim Gurpinar,
Xu Zhang, Elizabeth R. Rayburn, Charnell I. Sommers, Xinyi Yang,
Sadanandan E. Velu, Wei Wang and Ruiwen Zhang
Article: Preclinical Pharmacology of BA-TPQ, a Novel Synthetic
Iminoquinone Anticancer Agent
Mar. Drugs 2010, 8(7), 2129-2141; doi:10.3390/md8072129
http://www.mdpi.com/1660-3397/8/7/2129

Hedi Indra Januar, Ekowati Chasanah, Cherie A. Motti, Dianne M. Tapiolas,
Catherine H. Liptrot and Anthony D. Wright
Article: Cytotoxic Cembranes from Indonesian Specimens of the Soft Coral
Nephthea sp.
Mar. Drugs 2010, 8(7), 2142-2152; doi:10.3390/md8072142
http://www.mdpi.com/1660-3397/8/7/2142

Robert J. French, Doju Yoshikami, Michael F. Sheets and Baldomero M.
Olivera
Review: The Tetrodotoxin Receptor of Voltage-Gated Sodium
Channels—Perspectives from Interactions with μ-Conotoxins
Mar. Drugs 2010, 8(7), 2153-2161; doi:10.3390/md8072153
http://www.mdpi.com/1660-3397/8/7/2153

Fernando Scala, Ernesto Fattorusso, Marialuisa Menna, Orazio
Taglialatela-Scafati, Michelle Tierney, Marcel Kaiser and Deniz Tasdemir
Article: Bromopyrrole Alkaloids as Lead Compounds against Protozoan
Parasites
Mar. Drugs 2010, 8(7), 2162-2174; doi:10.3390/md8072162
http://www.mdpi.com/1660-3397/8/7/2162

Anne-Laure Deniau, Paul Mosset, Frédérique Pédrono, Romain Mitre,
Damien Le Bot and Alain B. Legrand
Review: Multiple Beneficial Health Effects of Natural Alkylglycerols from
Shark Liver Oil
Mar. Drugs 2010, 8(7), 2175-2184; doi:10.3390/md8072175
http://www.mdpi.com/1660-3397/8/7/2175

Maria Wiese, Paul M. D’Agostino, Troco K. Mihali, Michelle C. Moffitt
and Brett A. Neilan
Review: Neurotoxic Alkaloids: Saxitoxin and Its Analogs
Mar. Drugs 2010, 8(7), 2185-2211; doi:10.3390/md8072185
http://www.mdpi.com/1660-3397/8/7/2185

Liang Guo, Guang Liu, Ruo-Yu Hong and Hong-Zhong Li
Article: Preparation and Characterization of Chitosan Poly(acrylic acid)
Magnetic Microspheres
Mar. Drugs 2010, 8(7), 2212-2222; doi:10.3390/md8072212
http://www.mdpi.com/1660-3397/8/7/2212

More info

Jul
22 2010

Researchers worry that damage to the oceans could mean some species — and whatever chemicals they produce — will be lost before they’re found

Marc Slattery, a marine biologist by training, looks to sponges and coral as possible sources of drugs. As stationary species in the open ocean, these organisms have developed many chemical defenses to protect themselves. Slattery studies whether those chemicals could protect us, too. Maybe the same compounds that fend off fish could battle viruses, kill bacteria, and even fight cancer.

“These organisms are producing some nasty sorts of chemistry,” Slattery explains. “If you focus on the biotech side of things, there may be a drug in that” — or, he suspects, many.

After a long history of success on land, pharmacognosy — the search for substances in nature that have pharmaceutical potential — is finally getting its sea legs. Slattery, a pharmacognosy professor at the University of Mississippi, is one of the researchers scouring the oceans for cures.

Ocean acidification, warming water temperature and pollution all threaten sensitive corals and the symbiotic species that live on the reefs. Says Michael Lesser, a coral reef biologist at the University of New Hampshire who collaborates with Slattery, “We could lose something that could have great value to us as human beings, and not even know it.”

More info